Zacks Research Has Positive Estimate for FMS Q1 Earnings

Fresenius Medical Care AG (NYSE:FMS) – Zacks Research boosted their Q1 2025 earnings per share estimates for Fresenius Medical Care in a research note issued on Tuesday, March 18th. Zacks Research analyst I. Bandyopadhyay now expects that the company will earn $0.44 per share for the quarter, up from their previous estimate of $0.39. The consensus estimate for Fresenius Medical Care’s current full-year earnings is $1.51 per share. Zacks Research also issued estimates for Fresenius Medical Care’s Q2 2025 earnings at $0.47 EPS, Q3 2025 earnings at $0.54 EPS, Q4 2025 earnings at $0.56 EPS, FY2025 earnings at $2.01 EPS, Q1 2026 earnings at $0.48 EPS, Q2 2026 earnings at $0.49 EPS, Q3 2026 earnings at $0.60 EPS, FY2026 earnings at $2.19 EPS and FY2027 earnings at $2.07 EPS.

A number of other research analysts have also recently commented on the stock. StockNews.com raised shares of Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Truist Financial upped their price objective on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the stock a “hold” rating in a report on Monday, January 6th. Finally, Bank of America upgraded shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a report on Monday, December 2nd.

Fresenius Medical Care Stock Performance

Shares of Fresenius Medical Care stock opened at $24.79 on Thursday. The firm has a market cap of $14.54 billion, a PE ratio of 20.48, a price-to-earnings-growth ratio of 0.76 and a beta of 0.99. The company has a quick ratio of 1.02, a current ratio of 1.37 and a debt-to-equity ratio of 0.42. Fresenius Medical Care has a 52 week low of $17.93 and a 52 week high of $25.25. The business’s fifty day simple moving average is $23.78 and its 200-day simple moving average is $22.29.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in FMS. Millennium Management LLC boosted its position in Fresenius Medical Care by 5,297.5% in the 4th quarter. Millennium Management LLC now owns 722,238 shares of the company’s stock valued at $16,351,000 after buying an additional 708,857 shares during the period. Integral Health Asset Management LLC boosted its holdings in Fresenius Medical Care by 33.3% in the fourth quarter. Integral Health Asset Management LLC now owns 600,000 shares of the company’s stock valued at $13,584,000 after purchasing an additional 150,000 shares during the period. Northern Trust Corp grew its stake in Fresenius Medical Care by 45.9% during the 4th quarter. Northern Trust Corp now owns 362,190 shares of the company’s stock worth $8,200,000 after purchasing an additional 113,953 shares in the last quarter. Moran Wealth Management LLC increased its holdings in Fresenius Medical Care by 9.1% during the 4th quarter. Moran Wealth Management LLC now owns 254,710 shares of the company’s stock worth $5,767,000 after purchasing an additional 21,334 shares during the period. Finally, ABC Arbitrage SA acquired a new stake in Fresenius Medical Care in the 4th quarter valued at about $4,215,000. Hedge funds and other institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.